Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 765063 +/- Ezabenlimab in Japanese Patients with Advanced Solid Tumors
NCT04653142Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Dec 2020
- Primary completion
- Apr 2022
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of BI 765063 in solid tumor (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Maximum Tolerated Dose up to 3 weeks and Dose Limiting Toxicity up to 3 weeks. Started Dec 2020; status: completed.
02
Drugs
BI 765063
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04653142.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04653142.